Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

ASAAP-plus Clinical evaluation of AntimalarialS tri-therapy with AtovAquone-Proguanil for treatment of uncomplicated malaria in African children

Coordinator
Bernhard-Nocht-Institut Fuer Tropenmedizin, Germany
Runs
1 January 2024 to 31 December 2026
Status
Running
EU funding
€1.5m
Total cost
€1.5m
Partners
7 organisations in 7 countries
Type
Research and Innovation Action
Grant agreement
101145769

What the project is doing

In the project's own words, from its summary on CORDIS.

Susceptibility to Artemisinin-based combination therapies (ACTs) currently remains high among the African Plasmodium falciparum population, but resistant mutant has been detected recently. To mitigate the risk of resistance leading to a dramatic increase in malaria related mortality, more efficient ACTs need to be urgently explored for quick deployment in Africa. Artemether-lumefantrine (AL) is widely used and shows high efficacy and favourable safety in Africa but needs to be protected to increase its useful lifespan.

Atovaquone-proguanil (AP) is highly efficacious, safe and resistant parasites are not circulating in any endemic area. AP targets multiple parasite stages -liver and blood in human host, and mosquito- through an independent mode of action, limiting the risk of cross-resistance with current ACTs. The aim of the project is to assess the efficacy of a triple-therapy associating artemether-lumefantrine (AL) and atovaquone-proguanil (AP) for the treatment of uncomplicated P. falciparum malaria in African children in a non-inferiority comparator-controlled trial.

A phase III clinical trial will be conducted to compare safety and cure rate of a 3-day treatment course with AL+AP versus AL in 1,664 consenting 6 to 70 months children with uncomplicated malaria from Benin, Gabon, Ghana and Mali. The main outcome will be cure rate at day-42, excluding reinfections. Antimalarial pharmacokinetic parameters and post-treatment prophylactic efficacy will be estimated for the two treatments and compared.

Sub-studies will look at transmission-blocking efficacy through membrane-feeding assays and gametocyte dynamics, drug resistance selection. By proofing that AL+AP has safety and cure rate similar to AL, this project will lead to important public health-level benefits by provision of a first candidate regimen to be deployed when ACT resistance spreads throughout Africa and by decreasing human to mosquito transmission.

Topics

Who is involved

OrganisationCityCountryRole
Bernhard-Nocht-Institut Fuer TropenmedizinHamburgGermanyCoordinator
Institut Des Sciences Et TechniquesBobo DioulassoBurkina FasoParticipant
Institut De Recherche Clinique Du Benin (ircb)CotonouBJParticipant
Institut De Recherche Pour Le DeveloppementMarseilleFranceParticipant
Centre de Recherches Medicales de LambarénéLambarénéGAParticipant
Kwame Nkrumah University of Science and Technology KumasiKumasiGhanaParticipant
Universite Des Sciences Des Techniques Et Des Technologies De BamakoBamakoMLParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI